Latest News and Press Releases
Want to stay updated on the latest news?
-
Upstream reports third quarter 2024 financial results and recent corporate achievements
-
Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares
-
Upstream Bio announces pricing of upsized initial public offering
-
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
-
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
-
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
-
Paris, 8 septembre 2020, 7h30 AB Science présentera les résultats de son étude de phase 3 dans l’asthmesévère au Congrès Annuel International de European Respiratory Society ...
-
Paris, 08 September 2020, 7.30am AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract...
-
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
-
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...